Form 4: Korro Bio CEO Ram Aiyar Granted Stock Options
SEC Form 4 Filing
Korro Bio's CEO, Ram Aiyar, was granted stock options for 100,000 shares on February 3, 2025, according to a Form 4 filing.
Summary
- Ram Aiyar, the President and CEO of Korro Bio, Inc., was granted stock options to purchase 100,000 shares of common stock.
- The options were granted on February 3, 2025, with an exercise price of $33.50 per share.
- The options vest in 48 equal monthly installments starting February 3, 2025, contingent upon continued service.
- Aiyar also granted a Limited Power of Attorney to Vineet Agarwal, Jeffrey Cerio, and Oliver Dolan to handle SEC filings on his behalf.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no immediate negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Amgen, Gilead Sciences, and Biogen to incentivize performance and retain key personnel.
- The vesting schedule of 48 months is also typical, aligning with industry practices for long-term incentive plans.
- The size of the grant (100,000 shares) would need to be compared to similar-sized companies and executive roles to determine if it is within industry norms.
Stakeholder Impact
- Shareholders: The stock option grant could potentially dilute existing shareholders if the options are exercised.
- Employees: The grant could have a positive impact on employee morale as it signals confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction (grant of stock options) |
| 02/03/2025 | Vesting start date for the stock options |
| 02/04/2025 | Date of execution for the Limited Power of Attorney |
| 02/05/2025 | Date of signature for the Form 4 filing |
| 02/02/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.